{"href":"http://player.captivate.fm/services/oembed?url=http%3A%2F%2Fplayer.captivate.fm%2Fepisode%2F7eee434b-8f5f-4c5e-a212-c6d9f26aaaeb","version":"1.0","provider_name":"Captivate.FM","provider_url":"https://www.captivate.fm","width":600,"height":200,"type":"rich","html":"<iframe style=\"width: 100%; height: 200px;\" title=\"Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)\" frameborder=\"0\" scrolling=\"no\" allow=\"clipboard-write\" seamless src=\"http://player.captivate.fm/episode/7eee434b-8f5f-4c5e-a212-c6d9f26aaaeb\"></iframe>","title":"Kent Holtorf, MD - LDN should be considered a first-line therapy for CFS/FM (2019 Conference) (LDN, low dose naltrexone)","description":"","thumbnail_width":300,"thumbnail_height":300,"thumbnail_url":"https://artwork.captivate.fm/337c6759-0cde-4451-92b0-26e3ef4faa4b/untitled.png"}